Table 1.
Demographic and clinical characteristics; y = years; * WHO classification 2016 [22]
| Value (%) | |
|---|---|
| Sex: male/female | 12 (57%) / |
| 9 (43%) | |
| Mean age in years (range) | 51 (39–70 y) |
| Mean years of education (range) | 15 (12–20 y) |
| Handedness: right/left | 19 (90%) / 2 (10%) |
| Tumor location | |
| Left | 8 (38%) |
| • Frontal | 4 (19%) |
| • Temporal | 1 (5%) |
| • Parieto-occipital | 1 (5%) |
| • Occipital | 2 (10%) |
| Right | 12 (57%) |
| • Frontal | 7 (33%) |
| • Parietal | 1 (5%) |
| • Parieto-occipital | 1 (5%) |
| • Temporoparietal | 2 (10%) |
| • Hippocampal | 1 (5%) |
| Multifocal | 1 (5%) |
| Histology* | |
| WHO-grade III | 8 (38%) |
| • Anaplastic astrocytoma | 5 (24%) |
| • IDH mutant, MGMT methylated | 2 (10%) |
| • Not specified | 3 (14%) |
| • Anaplastic oligodendroglioma | 3 (14%) |
| • IDH mutant, MGMT methylated | 1 (5%) |
| • Not specified | 2 (10%) |
| WHO-grade IV | 13 (62%) |
| • Glioblastoma | 12 (57%) |
| • IDH mutant, MGMT methylated | 3 (14%) |
| • IDH mutant, MGMT wildtype | 3 (14%) |
| • IDH wildtype, MGMT methylated | 3(14%) |
| • Not specified | 3 (14%) |
| • Gliosarcoma | 1 (5%) |
| Type of surgery: | |
| • Resection under general anesthesia | 17 (81%) |
| • Awake resection | 1 (5%) |
| • Biopsy | 3 (14%) |
| Postoperative radiotherapy + temozolomide | 21 (100%) |
| Mean survival in years at neuropsychological evaluation | |
| • Grade III (range) | 12 (7-16y) |
| • Grade IV (range) | 8 (5-20y) |
| Caregivers (n = 15) | |
| Sex: male/female | 6 (40%) / 9 (60%) |